跳至主要内容
临床试验/NCT05279209
NCT05279209Unknown不适用

Catheter-directed Sclerotherapy Versus Surgical Resecction: Randomized Controlled Trial Comparing Ovarian Function and Therapeutic Efficacy After Treatment of Ovarian Endometrioma

Yonsei University1 个研究点 分布在 1 个国家目标入组 98 人开始时间: 2021年12月18日最近更新:
适应症

试验速览

阶段
不适用
入组人数
98
试验地点
1
主要终点
Serum AMH

研究概览

简要总结

The primary purpose of this study is to compare residual ovarian function and therapeutic efficacy of surgical resection and catheter-directed sclerotherapy for ovarian endometrioma

详细描述

Screening

  • History, Physical examination
  • Vital signs
  • Laboratory test (Serum AMH, CA-125, HE-4) / EKG / MRI
  • EHP-30

Intervention

  • Surgical enucleation or catheter-directed sclerotherapy
  • Laboratory test / EKG
  • Adverse event monitoring

Follow-up visit #1 (1 month)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
19 Years 至 60 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Women with symptomatic fibroids (age: 20 - 60 years old)

排除标准

  • Gynecologic malignancy
  • Ongoing infection or inflammation
  • Coagulopathy (platelet < 50,000 or INR > 1.5)
  • Extraovarian endometriosis
  • Serum AMH of 5 or higher
  • Drug allergy

结局指标

主要结局

Serum AMH

时间窗: Serum AMH at 12 months after catheter-directed sclerotherapy

Serum AMH: A measure of ovarian function

次要结局

  • serum CA-125(1, 6, 12 months)
  • hospital stay(duration of admission (days), up to 5 days)
  • EHP-30 (Endometriosis Health Profile-30)(6 and 12 months)
  • Recurrence(1, 6, and 12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验